A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. [electronic resource]
Producer: 20131018Description: 483-6 p. digitalISSN:- 1944-7884
- Adenine -- analogs & derivatives
- Adult
- Alanine Transaminase -- blood
- Anti-HIV Agents -- therapeutic use
- Aspartate Aminotransferases -- blood
- Atazanavir Sulfate
- Bilirubin -- blood
- Bone Density -- drug effects
- Carbamates -- therapeutic use
- Cobicistat
- Confidence Intervals
- Creatinine -- blood
- Deoxycytidine -- analogs & derivatives
- Double-Blind Method
- Drug Combinations
- Emtricitabine
- Female
- HIV Infections -- blood
- HIV-1 -- genetics
- Humans
- Male
- Oligopeptides -- therapeutic use
- Organophosphonates -- therapeutic use
- Pyridines -- therapeutic use
- Quinolones -- therapeutic use
- RNA, Viral -- blood
- Ritonavir -- therapeutic use
- Tenofovir
- Thiazoles -- therapeutic use
- Triglycerides -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.